

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 December 2020 (03.12.2020)



(10) International Publication Number
WO 2020/240472 A1

(51) International Patent Classification:
A61K 39/04 (2006.01)

(21) International Application Number:
PCT/IB2020/055083

(22) International Filing Date:
28 May 2020 (28.05.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/853,215 28 May 2019 (28.05.2019) US

(71) Applicant: **AYBAR ECOTECHNOLOGIES CORP.**
[DO/DO]; c/o Jaime R. Angeles; Angeles Pons 27 de
Febrero Av. No. 210; Suite 203, El Vergel, Santo Domingo,
10107 (DO).

(72) Inventor: **AYBAR-BATISTA, Diogenes**; Calle D, Manz.
VI, Edif. 14, Apt. 404, Residencial José Contreras, 11102
(DO).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND
METHODS OF USING THE SAME




FIG. 1

(57) Abstract: A wide-spectrum antibacterial pharmaceutical formulation comprising lysozyme and methods of treatment to prevent or cure diseases of bacterial etiology. Excipients provided in the pharmaceutical formulation comprising lysozyme enhance the stability and efficacy of lysozyme for treating bacterial infections in a mammal. The pharmaceutical formulation comprising lysozyme does not produce harmful secondary effects on tissues or organs during prolonged treatment. The formulation can be used to treat bacterial infections of the skin, mucosal regions, and administered into the blood stream of a patient, including respiratory infections. The formulation is useful in treating bacterial infections, including those that occur along with viral infections, particularly viral infections with a respiratory component, including COVID-19.

[Continued on next page]

WO 2020/240472 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*